Population differences in vaccine response (POPVAC)-2: the impact of environmental exposures and selected interventions on waning of vaccine-induced immune responses

Lead Research Organisation: London School of Hygiene & Tropical Medicine
Department Name: UNLISTED

Abstract

"Vaccines are a key weapon against infectious diseases which continue to have major detrimental impacts on health and development in in low-income countries (LICs). However, the effectiveness of some vaccines is reduced in tropical LICs and in rural vs urban settings. For example, the TB vaccine, BCG, provides 80% protection in some temperate countries, but 0% in some tropical settings.
A potential explanation for this phenomena includes exposure to parasites so to further understanding we will compare the vaccine responses for Ugandan adolescents among three groups: (1) urban-dwellers participating in our Entebbe Mother and Baby Study birth cohort who have low parasite exposure; (2) island communities where over 80% have schistosomiasis (a parasitic worm infection); (3) rural communities with high malaria exposure, where over 50% of school-children unknowingly have malaria. We will also look at how parasitic infections interact with other viral or bacterial infections (“transkingdom” effects) and how these indirect effects impact the immune system.
Finally, we will use statistical approaches to explore how the urban-rural environment, parasites, ""transkingdom"" effects and immune responses interrelate to determine vaccine responses. This fundamental information will contribute to the development of suitable vaccines for populations living in tropical LIC settings and inform public health policy to improve effectiveness of vaccine programmes."

Technical Summary

We propose that parasite infections contribute substantially to population differences in vaccine response; and that their effects are mediate We will test this hypothesis through four linked objectives among Ugandan adolescents. An immunisation programme comprising relevant live and inert vaccines will be given over one school year, with primary endpoints one month postimmunisation. A secondary endpoint at one year will assess response waning. 1. We will compare vaccine response profiles in urban adolescents (low parasite burden) with two rural cohorts, chosen for high schistosomiasis and high malaria prevalence. 2. We will establish whether current parasite infections have causal effects using individually-randomised, placebocontrolled interventions targeting the dominant infection in each rural cohort. Sample sizes will be robust, powered to detect vaccine response differences of 0.14log10 between study arms (modest effects compared to preliminary data). 3. We will assess herpesvirus-specific antibodies (Luminex), viral loads (droplet digital PCR) and cellular responses (ELISpot); and microbial translocation (MT; PCR for bacterial 16s ribosomal DNA, ELISA for lipopolysaccharide and other biomarkers). Markers of viral activation and MT will be related to parasite exposures and vaccine outcomes. 4. We will investigate pre-immunisation immunological characteristics using simple biomarkers and cell phenotyping, and with in-depth studies (including by mass cytometry) in smaller, representative groups; and link findings to both parasite exposures and vaccine outcomes. Our data will be integrated using causal mediation analyses to determine how urban-rural environment, parasites, "transkingdom" effects and immune responses relate to determine vaccine responses partly by "transkingdom" pathways (activation of herpesviruses; intestinal translocation of microbial products), and ultimately by pre-immunisation immune characteristics of the host.
 
Description Characterization of protein and glycan epitopes recognised following controlled human infection with Schistosoma mansoni in an endemic population
Amount € 149,846 (EUR)
Organisation Sixth Framework Programme (FP6) 
Department European and Developing Countries Clinical Trials Partnership
Sector Public
Country Netherlands
Start 08/2021 
End 08/2024
 
Description Deciphering the role of baseline transcription profile in determining vaccine responses.
Amount £11,443 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC/UVRI and LSHTM Research Unit Uganda
Sector Academic/University
Country Uganda
Start 01/2024 
End 07/2024
 
Description Innovations for vaccines against helminth infections (WORMVACS2.0)
Amount € 7,510,206 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 08/2023 
End 08/2028
 
Description NIHR Global Health Groupon on vaccines for vulnerable people in Africa (VAnguard)
Amount £2,984,447 (GBP)
Funding ID NIHR134531 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 08/2022 
End 02/2026
 
Description Supplement to MRC Programme Grant, Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic parasitic infections
Amount £200,000 (GBP)
Funding ID MC_PC 21034 
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 04/2022 
End 04/2023
 
Description Wellcome International Training Fellowship for Gyaviira Nkurunungi: "The impact of differential parasite exposure on immunological and metabolic predictors of vaccine response in the tropics"
Amount £296,299 (GBP)
Funding ID 224263/Z/21/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2022 
End 03/2025
 
Title Data supporting "Does schistosome or malaria exposure contribute to urban-rural differences in vaccine responses in Uganda? A causal mediation analysis using data from three linked randomised controlled trials." 
Description This dataset comprises individual-level data from participants in the POPVAC series of three randomised controlled trials. POPVAC A was conducted among schoolchildren from Koome islands, Uganda (a schistosomiasis-endemic setting), POPVAC B was conducted among schoolchildren from Jinja district, Uganda (a malaria-endemic setting), POPVAC C was conducted among schoolchildren from Entebbe, Uganda (a lower infection prevalence setting). 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact This dataset comprises individual-level data from participants in the POPVAC series of three randomised controlled trials. POPVAC A was conducted among schoolchildren from Koome islands, Uganda (a schistosomiasis-endemic setting), POPVAC B was conducted among schoolchildren from Jinja district, Uganda (a malaria-endemic setting), POPVAC C was conducted among schoolchildren from Entebbe, Uganda (a lower infection prevalence setting). 
URL https://datacompass.lshtm.ac.uk/id/eprint/3761
 
Title Data supporting "The effect of intensive praziquantel treatment on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands: results of the POPVAC A randomised, controlled trial" 
Description This dataset comprises individual-level data from participants in the POPVAC A randomised controlled trial. POPVAC A was an open-label randomised controlled trial of intensive versus standard intervention against Schistosoma mansoni among schoolchildren (9-17 years) in Koome islands, Uganda (ISRCTN60517191). The aim of the trial was to comprehensively address the hypothesis that Schistosoma mansoni infection causes suppression of responses to unrelated vaccines and that this effect can be reversed by intensive treatment with praziquantel. The trial population was selected to comprise children at intense risk of exposure to Schistosoma mansoni infection in a "hot-spot", island setting in Lake Victoria, Uganda. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of intensive treatment of Schistosoma mansoni on immune response to vaccines with different characteristics. 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact This dataset comprises individual-level data from participants in the POPVAC A randomised controlled trial. POPVAC A was an open-label randomised controlled trial of intensive versus standard intervention against Schistosoma mansoni among schoolchildren (9-17 years) in Koome islands, Uganda (ISRCTN60517191). 
URL https://datacompass.lshtm.ac.uk/id/eprint/3758
 
Title Data supporting "The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda: results of the POPVAC B randomised, controlled trial" 
Description This dataset comprises individual-level data from participants in the POPVAC B randomised controlled trial. POPVAC B was a randomised, double-blind, placebo-controlled trial of the effect of malaria IPT with dihydroartemisinin-piperaquine (DP) on vaccine responses among schoolchildren (9-17 years) in Jinja district, Uganda (ISRCTN62041885). The aim of the trial was to comprehensively address the hypothesis that malaria infection causes suppression of responses to unrelated vaccines and that this effect can be reversed at least partially, by monthly intermittent preventive treatment (IPT) of malaria in high-transmission settings. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of IPT of malaria on immune response to vaccines with different characteristics. 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact Newly available database, likely to contribute to international collaborations on factors that determine vaccine response 
URL https://datacompass.lshtm.ac.uk/id/eprint/3759
 
Title Data supporting: "The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents: results of the POPVAC C randomised, controlled trial" 
Description This dataset comprises individual-level data from participants in the POPVAC C randomised controlled trial. POPVAC C was an open-label randomised controlled trial of Bacillus Calmette Guérin (BCG) revaccination versus no BCG among schoolchildren in Entebbe, Uganda (ISRCTN10482904). The aim of the trial was to comprehensively address the hypothesis that revaccination with BCG might enhance responses to unrelated vaccines. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of BCG revaccination on immune response to vaccines with different characteristics. 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact Newly available database, likely to contribute to international collaborations on factors that determine vaccine response 
URL https://datacompass.lshtm.ac.uk/id/eprint/3760
 
Description Arbovirology, UVRI 
Organisation Uganda Virus Research Institute
Department Department of Arbovirology, Emerging and Re-emerging Infections
Country Uganda 
Sector Public 
PI Contribution We are conducting the POPVAC research programme, samples from which will be processed by the department of arbovirology at UVRI
Collaborator Contribution They will undertake yellow fever plaque reduction neutralisation tests.
Impact Not yet
Start Year 2020
 
Description Dr Cecile Crosnier 
Organisation University of York
Department Department of Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution We are working with Dr Cecile Crosnier on her MRC Career Development Award to extend Dr Moses Egesa's work "Epitope mapping of schistosome tegument and alimentary tract proteins in humans".
Collaborator Contribution Dr Crosnier has availed a library of recombinant parasite proteins for use in assays with samples from Schistosomiasis endemic populations to identify the targets of protective immunity.
Impact A large resource of recombinant parasite proteins to identify the targets of protective immunity
Start Year 2022
 
Description Dr James Hewitson 
Organisation University of York
Department Department of Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution James Hewitson
Collaborator Contribution With Dr Hewitson, we have applied and successfully obtained two grants from GCRF and one from the MRC. Dr Moses Egesa has been seconded as Post-doctoral Research Associate to the Hewitson Laboratory to study (1) in vivo anti-schistosome immune responses in endemic populations using humanised mouse models of schistosomiasis and (2) infection-induced changes in haematopoiesis. Dr Egesa underwent training in animal models of schistosomiasis, cutting-edge technologies (humanised mouse models) and specialised immunological techniques (e.g. confocal microscopy, multi-parameter flow cytometry)
Impact Dr Egesa completed accredited training for personnel working under the Animals (Scientific Procedures) Act 1986; EU Modules achieved: PIL AB (by The University of Newcastle) EU Modules achieved: PIL C (by The Royal Veterinary College)
Start Year 2019
 
Description Edridah Tukahebwa, Narcis Kabatereine 
Organisation Ministry of Health, Uganda
Department Vector Control Division
Country Uganda 
Sector Public 
PI Contribution These collaborators have expertise in the epidemiology, diagnosis and control of helminth infections. They also understand policy implications and applications. We have worked with them on implementation of all our helminth related work in Uganda.
Collaborator Contribution These collaborators have expertise in the epidemiology, diagnosis and control of helminth infections. They also understand policy implications and applications.
Impact Numerous papers and presentations Stakeholders' meetings Grants
 
Description Helen McShane, Adrian Hill, Alex Mentzer 
Organisation University of Oxford
Department Jenner Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on (1) genetic studies on the response to infant vaccines (on-going) (2) a trial investigating the impact of schistosomiasis on the response to candidate TB vaccine MVA85A (completed) (3) a trial of ChAdOx1 85A and MVA85A as a new regimen for boosting TB immunity in adolescents. We are conducting the trial in Uganda (about to start)
Collaborator Contribution For (1) the partners provide expertise in genetics For (2) and (3) the partners are providing the vaccine, as well as contributing expertise in TB vaccine trials
Impact Publications and conference presentations DPhil for Alex Mentzer (completed) Contributions to PhDs for Swaib Lule (completed), Anne Wajja (on-going) and Beatrice Nassanga (about to commence)
Start Year 2017
 
Description Innovations for vaccines against helminth infections (WORMVACS2.0) 
Organisation Center of Medical Research Lambaréné
Country Gabon 
Sector Academic/University 
PI Contribution The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines.
Collaborator Contribution The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias
Impact Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing.
Start Year 2023
 
Description Innovations for vaccines against helminth infections (WORMVACS2.0) 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines.
Collaborator Contribution The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias
Impact Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing.
Start Year 2023
 
Description Innovations for vaccines against helminth infections (WORMVACS2.0) 
Organisation Moderna
Country United States 
Sector Private 
PI Contribution The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines.
Collaborator Contribution The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias
Impact Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing.
Start Year 2023
 
Description Innovations for vaccines against helminth infections (WORMVACS2.0) 
Organisation Texas Tech University Health Sciences Center
Country United States 
Sector Academic/University 
PI Contribution The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines.
Collaborator Contribution The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias
Impact Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing.
Start Year 2023
 
Description MRC/UVRI Uganda Unit - London School of Hygiene & Tropical Medicine 
Organisation MRC/UVRI Uganda Research Unit on AIDS
Country Uganda 
Sector Public 
PI Contribution I and my research team are based at the MRC/UVRI Unit. I lead a research programme there. In 2018 the Unit became a part of the London School of Hygiene and Tropical Medicine so this ceased to be a collaboration in the earlier sense of the word.
Collaborator Contribution The MRC/UVRI Unit hosts the research, providing facilities, administration and research support
Impact This collaboration has resulted in more than 80 research publications, several research grants, two Wellcome Trust funded and one EDCTP funded research capacity building grants, much training at undergraduate, Masters, PhD and post-doctoral level.
 
Description Maria Yazdanbakhsh; Meta Roestenberg 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution We are undertaking collaborations with LUMC department of parasitology on immuno-epidemiological effects of helminths, and on schistosomiasis vaccine development including controlled human infection models for schistosomiasis (CHI-S) In 2019 we developed a proposal for establishing the CHI-S in Uganda which the Wellcome Trust panel supported for funding. We are awaiting the award letter.
Collaborator Contribution The partners provide technical expertise, particularly in parasite immunology and
Impact PhD: co-supervision to completion of two fellows, Gyaviira Nkurunungi and Moses Egesa (both completed successfully in 2019). Publications and conference presentations. New grants for preparatory work on Sm-CHI
Start Year 2011
 
Description Metabolic phenotypes and vaccine response 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution We are collaborating with Prof. Richard Grencis ( University of Manchester) on work to understand the association between pre-vaccination metabolic phenotype and the post-vaccination response to a panel of 5 vaccines (BCG, HPV, Yellow Fever, Oral typhoid, Tetanus/Diphtheria) among adolescents participating in a set of Ugandan trials. In Uganda, we will extract metabolites from plasma samples, and send them to Manchester for liquid chromatography-mass spectrometry (LC-MS) to quantitate metabolites. Results will be returned to us in Uganda for high dimensional analysis.
Collaborator Contribution The Manchester team will conduct the LC-MS experiments.
Impact We have worked on a Material Transfer Agreement and a collaboration agreement with the Manchester team.
Start Year 2023
 
Description MoH UNEPI programme 
Organisation Uganda National Expanded Programme on Immunisation
Country Uganda 
Sector Public 
PI Contribution We are running the POPVAC trials which will provide EPI with information on the effects of parasitic infections on the response to widely used vaccines.
Collaborator Contribution The EPI programme is providing HPV vaccine for individuals in the POPVAC trials. As well, they are supporting us with training and advice.
Impact None as yet
Start Year 2018
 
Description NIHR Global Health Group, VAnguard 
Organisation Uganda Christian University
Country Uganda 
Sector Academic/University 
PI Contribution This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa.
Collaborator Contribution Partners are leading various work packages
Impact No outputs yet.
Start Year 2022
 
Description NIHR Global Health Group, VAnguard 
Organisation Uganda Virus Research Institute
Country Uganda 
Sector Public 
PI Contribution This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa.
Collaborator Contribution Partners are leading various work packages
Impact No outputs yet.
Start Year 2022
 
Description NIHR Global Health Group, VAnguard 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa.
Collaborator Contribution Partners are leading various work packages
Impact No outputs yet.
Start Year 2022
 
Description NIHR Global Health Group, VAnguard 
Organisation Wellcome Trust
Department KEMRI-Wellcome Trust Research Programme
Country Kenya 
Sector Academic/University 
PI Contribution This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa.
Collaborator Contribution Partners are leading various work packages
Impact No outputs yet.
Start Year 2022
 
Description Global Challenges & Opportunities for Vaccines 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A workshop on the immunomodulating effects of helminth infection.
Year(s) Of Engagement Activity 2023
 
Description Hypovax: connecting people to reverse vaccine hyporesponsiveness 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A workshop on population differences in vaccine responses and how hyporesponsiveness could be addressed.
Year(s) Of Engagement Activity 2024
URL https://hypovax.org/
 
Description VAnguard Global Health Group Launch event 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact An event engaging collaborators, community members and other stakeholders to initiate and plan for the NIHR Global Health Group, VAnguard
Year(s) Of Engagement Activity 2022
 
Description WORMVACS consortium meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Inaugural meeting of the WORMVACS-2 consortium
Year(s) Of Engagement Activity 2023
URL https://linq-management.com/news/wormvacs-kickoff-meeting-in-leiden.html